News/ News/ Oncology Failed trial nixes another FDA approval, this time for BMS’ Istodax Phil Taylor Bristol-Myers Squibb, fda, Istodax, lymphoma, Oncology 0 Comment Bristol-Myers Squibb’s HDAC inhibitor Istodax has been on the US market for a decade as a treatment for Share X Failed trial nixes another FDA approval, this time for BMS’ Istodax https://pharmaphorum.com/news/failed-trial-nixes-another-fda-approval-this-time-for-bms-istodax/
Bristol-Myers Squibb, fda, Istodax, lymphoma, Oncology
0 Comment
